2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Insulin lispro U-200 should not be mixed with any other insulin, nor should it be administered intravenously or used with insulin pumps
The documentation should reflect the clinical reality of why your provider is prescribing it
So this guide covers both ends: why Ozempic gets paused for surgery in the first place, and the clearer part most articles skip, how to know you are actually ready to restart
For appetite and glucose studies